

A Randomised Study of MVP (Mitomycin-C, Vinblastine and Moderate Dose Cisplatin) Three versus Six Cycles in Advanced Non-Small Cell Lung Cancer

| | | |
|--|---|--|
| Submission date 19/08/2002 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered |
| Registration date 19/08/2002 | Overall study status Completed | <input type="checkbox"/> Protocol |
| Last Edited 10/10/2012 | Condition category Cancer | <input type="checkbox"/> Statistical analysis plan |
| | | <input type="checkbox"/> Results |
| | | <input type="checkbox"/> Individual participant data |
| | | <input type="checkbox"/> Record updated in last year |

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Lung (non-small cell) cancer

Interventions

All patients receive chemotherapy with MVP (mitomycin-C, vinblastine and moderate dose cisplatin) repeated every 21 days for three courses. Mitomycin-C is given with the first and second course only.

Patients responding to treatment or with stable disease are randomised to either:

1. Arm A: Three further cycles of MVP chemotherapy. Mitomycin-C is given with the first and third course only.
2. Arm B: Best supportive care.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Mitomycin-C, Vinblastine and Moderate Dose Cisplatin

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/2000

Completion date

31/12/2005

Eligibility**Key inclusion criteria**

1. Histological evidence of non-small cell lung cancer
2. Stage IIIb or IV disease not eligible for neoadjuvant chemotherapy and/or radical radiotherapy
3. Performance status <2 (Zubrod-Eastern Cooperative Oncology Group [ECOG]-World Health Organisation [WHO] scale)
4. Adequate renal, bone marrow, and lung function tests unless due to metastatic disease
5. Patients must already have achieved symptom relief after three cycles of MVP chemotherapy
6. No uncontrolled infection
7. No previous conventional chemotherapy prior to MVP. One prior phase I/II new drug is allowed
8. No medical contraindications to treatment protocols

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/2000

Date of final enrolment

31/12/2005

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

The Royal Marsden NHS Foundation Trust (UK)

Sponsor details

Downs Road

Sutton

England

United Kingdom

SM2 5PT

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/0008wzh48>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Royal Marsden Hospital (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration